Frontline Targeted Therapy for METex14 Skip Mutation in NSCLC: Latest Updates from 2021 – West

bookLearning Objectives

  1. Review METex14 skip mutation-driven lung cancer as an important subgroup with
    unmet needs.
  2. Discuss emerging targeted therapies in patients with METex14 skip mutations.
  3. Discuss latest 2021 clinical data for targeted therapies against METex14 skip
    mutations (ASCO/WCLC/ESMO 2021). 



Wednesday, October 20, 2021

Local Time

  • Timezone: America/New_York
  • Date: Wednesday, October 20, 2021
  • Time: 3:00 pm - 4:00 pm


Registration is complimentary and restricted to healthcare professionals. Please click the button below to complete the transaction:

personAbout the Faculty

Dr. Barbara Melosky
Dr. Barbara Melosky
Dr. Melosky is a Clinical Professor of medicine at the University of British Columbia and a medical oncologist in Vancouver at the British Columbia Cancer Agency. Dr. Melosky specializes in the field of thoracicmalignancy. She is head of the Lung Tumor Group at BC Cancer. She sits on the Executive Lung Site Committee for Canadian Clinical Trials Group CTTG. Dr. Melosky chaired the Canadian Lung Cancer Conference for the last 21years, which is attended by over 500participants.She organizes and chairs the Lung Cancer Journal Club. She is chair and created the British Columbia Lung Cancer Biobank. She is published extensively and is considered a national and international expert in thoracic malignancies.
Dr. Johan Vansteenkiste
Johan Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital. Professor Vansteenkiste studied Medicine at the University of Leuven before becoming a Board Certified PulmonologistOncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the University of Leuven in 1996.

Professor Vansteenkiste is an active member of different international societies such as ESMO, IASLC, ASCO, ERS and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and member of the ERS School Board in 2009-2012. He was in the Board of Directors of IASLC in 2009-2013. He is member of the ESMO Lung Educational Group and Guidelines Group, and chaired one of the ESMO European Lung Cancer

He is principal investigator /co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor at Annals of Oncology, member of the editorial board of several other journals, and author / co-author of more than 350 peer-reviewed papers and book chapters on Respiratory Oncology. Current Web of Science H-index is 73, awarded by 2020 Highly Cited Researcher Award by Web of Science. Recipient of the 2021 ESMO/IASLC Heine H. Hansen Award for outstanding contributions to education and research in lung cancer.

This program has been made possible through unrestricted support from Novartis.